UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/594,448	05/15/2007	Akira Nakagawara	Q97365	1244
23373 SUGHRUE MI	7590 12/15/200 ON, PLLC	EXAMINER		
2100 PENNSYLVANIA AVENUE, N.W.			CARLSON, KAREN C	
SUITE 800 WASHINGTON, DC 20037		ART UNIT	PAPER NUMBER	
			1656	
			MAIL DATE	DELIVERY MODE
			12/15/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Comment	10/594,448	NAKAGAWARA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Karen Cochrane Carlson	1656				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
<i>,</i> —	-					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
closed in accordance with the practice under Lx parte Quayle, 1930 C.D. 11, 400 C.C. 210.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-10</u> is/are pending in the application.	4) Claim(s) 1-10 is/are pending in the application.					
4a) Of the above claim(s) is/are withdraw	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	•					
8) Claim(s) <u>1-10</u> are subject to restriction and/or e	lection requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 						
					3. Copies of the certified copies of the priority documents have been received in this National Stage	
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date						
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08)	ite atent Application					
Paper No(s)/Mail Date 6) Other:						

Art Unit: 1656

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1, 2, drawn to a method for screening a preapoptotic compound that increases the binding between p73 and IKK.

Group 2, claim(s) 3, 4, drawn to a method for screening a preapoptotic compound that decreases the binding between p73 and IKK.

Group 3, claim(s) 5, drawn to polypeptide SEQ ID NO: 24.

Group 4, claim(s) 6, drawn to nucleic acid encoding polypeptide SEQ ID NO: 24.

Group 5, claim(s) 7, drawn to polypeptide SEQ ID NO: 25.

Group 6, claim(s) 8, drawn to nucleic acid encoding polypeptide SEQ ID NO: 25.

Group 7, claim(s) 7, drawn to polypeptide SEQ ID NO: 26.

Group 8, claim(s) 8, drawn to nucleic acid encoding polypeptide SEQ ID NO: 26.

The inventions listed as Groups 1-8 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the claims describe 2 general inventive concepts involving "controlling p73 apoptosis induction activity by means of a protein that acts on p73," but because these two general inventive concepts do not share a novel special technical feature, this international application does not comply with the requirement of unity of invention in accordance with Enforcement Rule 13 (PCT Rules 13.1, 13.2 and 13.3).

Application/Control Number: 10/594,448 Page 3

Art Unit: 1656

.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson whose telephone number is 571-272-0946. The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/594,448 Page 4

Art Unit: 1656

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Karen Cochrane Carlson/ Primary Examiner, Art Unit 1656